Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
Concert Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference LEXINGTON, MASS. — Concert Pharmaceuticals, Inc.™, the first company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced today that it will be presenting at the 26th
View HTML
Toggle Summary Concert Pharmaceuticals Names W. James O’Shea and Daniel Grau to Product Advisory Board
Concert Pharmaceuticals Names W. James O’Shea and Daniel Grau to Product Advisory Board LEXINGTON, Mass. — Concert Pharmaceuticals, Inc.™, the first company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced today the addition of two new members to
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare Conference
Concert Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare Conference LEXINGTON, MASS. — Concert Pharmaceuticals, Inc.™, the first company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced today that it will be presenting at
View HTML
Toggle Summary Concert Pharmaceuticals Raises $37 Million in Series C Financing
Broad Syndicate of New and Existing Investors
View HTML
Toggle Summary Concert Pharmaceuticals Named One of the "Fierce 15" Biotech Companies of 2008
June 24, 2008 Lexington, MA – Concert Pharmaceuticals, Inc. announced today that it has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotechnology companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on a
View HTML
Toggle Summary Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen; Results Presented at the North American Menopause Society's 2008 Annual Meeting
Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen; Results Presented at the North American Menopause Society's 2008 Annual Meeting Results Presented at the North American Menopause Society’s 2008 Annual Meeting Orlando, FL – Concert
View HTML
Toggle Summary Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial; Potential Best-in-Class Non-Hormonal Treatment for Vasomotor Symptoms
Potential Best-in-Class Non-Hormonal Treatment for Vasomotor Symptoms
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Concert Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference Lexington, MA - Concert Pharmaceuticals, Inc. announced today that it will be presenting at the Third Annual JMP Securities Healthcare Focus Conference, being held at the Le Parker Meridien in New York City.
View HTML
Toggle Summary Steven Bernitz Joins Concert Pharmaceuticals as Chief Business Officer
Steven Bernitz Joins Concert Pharmaceuticals as Chief Business Officer Lexington, MA – Concert Pharmaceuticals, Inc. today announced that Steven B. Bernitz has joined the company as its Senior Vice President and Chief Business Officer.  In this role, he will be a member of Concert’s executive
View HTML
Toggle Summary Concert Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference
Concert Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference Lexington, MA – Concert Pharmaceuticals, Inc. today announced that it will be presenting at the 2008 Boston Biotech R&D Conference being held at Harvard Medical School in Cambridge, Massachusetts.  Roger Tung, Ph.D.,
View HTML